机构:[1]The Second Clinical College, GuangzhouUniversity of Chinese Medicine,Guangzhou, People’s Republic of China[2]Chronic Disease ManagementOutpatient Clinic, The Second AffiliatedHospital of Guangzhou University ofChinese Medicine (Guangdong ProvincialHospital of Chinese Medicine),Guangzhou, People’s Republic of China[3]Renal Division, The Second AffiliatedHospital of Guangzhou University ofChinese Medicine (Guangdong ProvincialHospital of Chinese Medicine),Guangzhou, People’s Republic of China
Background: To transfer a paper-version Chinese and Western medication adherence scale for CKD into an electronic scale, and evaluate its validity, internal consistency and clinical implementation, and assess whether the transition is feasible in clinic. Methods: We built an e-version Chinese and Western medication adherence scale based on the Wen-JuanXing platform. CKD subjects' responses were applied to test the scale's validity and internal consistency. We retested some of the participants two weeks later randomly. We also tested the clinical application. Results: Of the 434 recruited patients, 228 responded. In exploratory factor analysis (EFA), the Kaiser-Meyer-Olkin (MVO) measure of sampling adequacy = 0.8 and Bartlett's approx. Chi-Square = 1340.0 (df = 105, p < 0.001). We extracted four common factors which could explain 61.47% of the variance. However, Item 15 "Have you changed a traditional Chinese medicine prescription yourself within the past month?" had factor loading = 0.3 and measure of sampling adequacy (MSA) = 0.5, meaning we could not enter it into the factor analysis. The internal consistency reliability for medication adherence was 0.9, with a Guttman split-half coefficient = 0.5 and a Spearman-Brown coefficient = 0.6. Cronbach's alpha was 0.9, 0.4 and 0.5 for the knowledge, belief and behavior domains, respectively. The correlation coefficient r of the test-retest reliability was -0.8 and was -0.8, 0.4, -0.3 in the knowledge, belief and behavior domains, respectively. Patients with comorbidities were more likely to respond. We detected no other significant differences in the clinical profiles between respondents and non-respondents. Conclusion: The e-version Chinese and Western medication adherence scales have undesirable construct validity and internal consistency. Thus, caution is needed in transitioning the paper-version scale into an e-version.
基金:
Science and Technology Planning Project of Guangdong Province, China: Establishment and Evaluation of the Medication Adherence Scale of Traditional Chinese and Western Medicine for Patients with Chronic Kidney Disease under Grant number 2014A020221087 and The National Key Research and Development Program of China: Establishment and Evaluation an Exposed Omics based Prediction Model on CKD Risk and Benefit Factors (Project No. 2019YFE0196300).
第一作者机构:[1]The Second Clinical College, GuangzhouUniversity of Chinese Medicine,Guangzhou, People’s Republic of China
通讯作者:
推荐引用方式(GB/T 7714):
Chen Hui-Fen,Lei Nuo,Xu Yan-Min,et al.Is E-Version Transition of the Medication Adherence Scale Feasible for CKD Management? A Pilot Study[J].PATIENT PREFERENCE AND ADHERENCE.2021,15:1785-1793.doi:10.2147/PPA.S323393.
APA:
Chen, Hui-Fen,Lei, Nuo,Xu, Yan-Min,Luo, Li,Zhang, Xian-Long...&Wu, Yi-Fan.(2021).Is E-Version Transition of the Medication Adherence Scale Feasible for CKD Management? A Pilot Study.PATIENT PREFERENCE AND ADHERENCE,15,
MLA:
Chen, Hui-Fen,et al."Is E-Version Transition of the Medication Adherence Scale Feasible for CKD Management? A Pilot Study".PATIENT PREFERENCE AND ADHERENCE 15.(2021):1785-1793